{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:31:29Z","timestamp":1794317489512,"version":"4.9.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.critrevonc.2023.104134","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T11:52:11Z","timestamp":1695210731000},"page":"104134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Infections in haematology patients treated with CAR-T therapies: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"192","author":[{"given":"Gemma K.","family":"Reynolds","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Spelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashmitha","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Longhitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Thursky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin W.","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.critrevonc.2023.104134_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2020.12.010","article-title":"Systematic review and meta-analysis of CD19-specific CAR-T cell therapy in relapsed\/refractory acute lymphoblastic leukemia in the pediatric and young adult population: safety and efficacy outcomes","volume":"21","author":"Aamir","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"10254","key":"10.1016\/j.critrevonc.2023.104134_bib2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104134_bib3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104134_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.03.004","article-title":"Early time-to-tocilizumab after B cell maturation antigen-directed chimeric antigen receptor T cell therapy in myeloma","volume":"27","author":"Banerjee","year":"2021","journal-title":"Transpl. Cell Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104134_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/ejh.13712","article-title":"Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells","volume":"108","author":"Beyar-Katz","year":"2022","journal-title":"Eur. J. Haematol."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104134_bib6","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2023.104134_bib7","article-title":"CAR-T cell therapy and infection: a review","author":"Bupha-Intr","year":"2020","journal-title":"Expert Rev. Anti-Infect. Ther."},{"issue":"SUPPL 2","key":"10.1016\/j.critrevonc.2023.104134_bib8","first-page":"371","article-title":"First report of the real-life prospective observational study \"CAR-T cell in diffuse large B-cell and primary mediastinal lymphomas\" of the italian society of hematology","volume":"39","author":"Chiappella","year":"2021","journal-title":"Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104134_bib9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104134_bib10","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1002\/jmv.27257","article-title":"Severe cytomegalovirus disease with encephalitis after CAR-T cell therapy: a rare but potentially fatal complication","volume":"93","author":"Cousin","year":"2021","journal-title":"J. Med Virol."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104134_bib11","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/ajh.26259","article-title":"Chimeric antigen receptor T\u2010cells safety: a pharmacovigilance and meta\u2010analysis study","volume":"96","author":"Dolladille","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104134_bib12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat. Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104134_bib13","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/ijc.33356","article-title":"Filgrastim associations with CAR T-cell therapy","volume":"148","author":"Gaut","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"SUPPL 1","key":"10.1016\/j.critrevonc.2023.104134_bib14","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2021-148792","article-title":"Outreach: results from a phase 2 study of lisocabtagene maraleucel (Liso-cel) administered as inpatient (INPT) or outpatient (outpt) treatment in the non-university setting in patients (pts) with r\/r large B-cell lymphoma (LBCL)","volume":"138","author":"Godwin","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104134_bib15","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/cid\/ciz1127","article-title":"Invasive mold infections after chimeric antigen receptor\u2013modified T-cell therapy: a case series, review of the literature, and implications for prophylaxis","volume":"71","author":"Haidar","year":"2019","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104134_bib16","doi-asserted-by":"crossref","first-page":"S275","DOI":"10.1016\/j.bbmt.2019.12.446","article-title":"Infectious complications of CAR T-cell therapy in non-hodgkin lymphoma","volume":"26","author":"Hayne","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"3 Supplement","key":"10.1016\/j.critrevonc.2023.104134_bib17","doi-asserted-by":"crossref","first-page":"S275","DOI":"10.1016\/j.bbmt.2019.12.446","article-title":"Infectious complications of CAR T-cell therapy in non-hodgkin lymphoma","volume":"26","author":"Hayne","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104134_bib18","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104134_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104134_bib20","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/cam4.3881","article-title":"Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104134_bib21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104134_bib22","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv."},{"issue":"SUPPL 1","key":"10.1016\/j.critrevonc.2023.104134_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2021-147913","article-title":"Lisocabtagene maraleucel (LISO-CEL), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2l) treatment in pati","volume":"138","author":"Kamdar","year":"2021","journal-title":"Blood"},{"issue":"10343","key":"10.1016\/j.critrevonc.2023.104134_bib24","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104134_bib25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10147-021-02033-4","article-title":"Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma","volume":"27","author":"Kato","year":"2022","journal-title":"Int J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104134_bib26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","article-title":"Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors","volume":"10","author":"Kochenderfer","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2023.104134_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130195","article-title":"Comparation of CART19 and autologous stem-cell transplantation for refractory\/relapsed non-Hodgkin's lymphoma","volume":"5","author":"Li","year":"2019","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104134_bib28","doi-asserted-by":"crossref","first-page":"569","DOI":"10.21037\/tcr-22-344","article-title":"Efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy in the treatment of relapsed and refractory multiple myeloma: a systematic-review and meta-analysis of clinical trials","volume":"11","author":"Li","year":"2022","journal-title":"Transl. Cancer Res"},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104134_bib29","first-page":"739","article-title":"Infectious complications following chimeric antigen receptor T-cell therapy for a hematologic malignancy within 28 days","volume":"42","author":"Li","year":"2021","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"SUPPL 2","key":"10.1016\/j.critrevonc.2023.104134_bib30","first-page":"235","article-title":"Early GCSF after ANTI-CD19 car t-cells decreases incidence of febrile neutropenia without worsening toxicities and expansion of CAR T-cells in refractory\/relapsed B-cell lymphoma","volume":"5","author":"Lievin","year":"2021","journal-title":"HemaSphere"},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104134_bib31","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.clml.2021.02.002","article-title":"Epidemiology and risks of infections in patients with multiple myeloma managed with new generation therapies","volume":"21","author":"Lim","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2023.104134_bib32","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1182\/blood-2019-125162","article-title":"Impact and safety of chimeric antigen receptor T cell therapy in vulnerable older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"134","author":"Lin","year":"2019","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.critrevonc.2023.104134_bib33","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1182\/bloodadvances.2022007474","article-title":"Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma","volume":"6","author":"Little","year":"2022","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104134_bib34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104134_bib35","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2021","journal-title":"New Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104134_bib36","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104134_bib37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"49","author":"Los-Arcos","year":"2021","journal-title":"Infection"},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104134_bib38","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jtct.2022.09.007","article-title":"Impact of cytomegalovirus replication in patients with aggressive B cell lymphoma treated with chimeric antigen receptor T cell therapy","volume":"28","author":"M\u00e1rquez-Algaba","year":"2022","journal-title":"Transplant. Cell. Ther."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104134_bib39","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"New Engl. J. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104134_bib40","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid. Synth."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104134_bib41","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.critrevonc.2023.104134_bib42","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104134_bib43","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat. Med."},{"issue":"SUPPL 1","key":"10.1016\/j.critrevonc.2023.104134_bib44","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-138865","article-title":"Steroid use, advanced stage disease and >=3 lines of prior chemotherapy are associated with a higher risk of infection following CD19 CAR T-cell therapy for B-NHL: Real world data from a large UK center","volume":"136","author":"Neill","year":"2020","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104134_bib45","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.critrevonc.2023.104134_bib46","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2023.104134_bib47","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/blood-2019-129421","article-title":"Impact of bridging chemotherapy on clinical outcomes of CD19 CAR T therapy in relapse\/refractory diffuse large B- cell lymphoma in real world experience","volume":"134","author":"Paillassa","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104134_bib48","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen Receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.critrevonc.2023.104134_bib49","series-title":"Infectious Complications in Biologic and Targeted Therapies","first-page":"315","article-title":"Infection associated with the use of CAR T cells","author":"Puerta-Alcalde","year":"2022"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104134_bib50","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3324\/haematol.2021.278288","article-title":"Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study","volume":"107","author":"Ram","year":"2022","journal-title":"Haematologica"},{"issue":"SUPPL 1","key":"10.1016\/j.critrevonc.2023.104134_bib51","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1182\/blood-2021-149579","article-title":"The CAR-hematotox identifies patients at high risk for prolonged neutropenia, infectious complications and prolonged hospitalization following CD19-CART in R\/R LBCL","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"SUPPL 1","key":"10.1016\/j.critrevonc.2023.104134_bib52","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1182\/blood-2021-153277","article-title":"Analysis of outcomes and predictors of response in patients with relapsed mantle cell lymphoma treated with brexucabtagene autoleucel","volume":"138","author":"Romancik","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104134_bib53","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104134_bib54","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104134_bib55","first-page":"40","article-title":"meta: an R package for meta-analysis","volume":"7","author":"Schwarzer","year":"2007","journal-title":"R. N."},{"issue":"10299","key":"10.1016\/j.critrevonc.2023.104134_bib56","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104134_bib57","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bjh.18335","article-title":"Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: a systematic review and meta-analysis","volume":"198","author":"Shargian","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"SUPPL 1","key":"10.1016\/j.critrevonc.2023.104134_bib58","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-143353","article-title":"Incidence and causes of prolonged hematologic toxicity after chimeric antigen receptor T cell therapy: a city of hope (COH) experience","volume":"136","author":"Shouse","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.104134_bib59","article-title":"Infectious complications of CAR T-cell therapy: a clinical update","volume":"8","author":"Stewart","year":"2021","journal-title":"Ther. Adv. Infect. Dis."},{"issue":"Supplement 15","key":"10.1016\/j.critrevonc.2023.104134_bib60","article-title":"Hematopoietic recovery and immune reconstitution after axi-cel CAR T-cell therapy in patients with relapsed\/refractory large B-cell lymphoma","volume":"37","author":"Strati","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104134_bib61","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2016.07.025","article-title":"Infection risk with immunomodulatory and proteasome inhibitor\u2013based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis","volume":"67","author":"Teh","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104134_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01247","article-title":"Predicting risk of infection in patients with newly diagnosed multiple myeloma: utility of immune profiling","volume":"8","author":"Teh","year":"2017","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2023.104134_bib63","doi-asserted-by":"crossref","DOI":"10.1080\/14787210.2022.2128762","article-title":"Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis","author":"Telli Dizman","year":"2022","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"10.1016\/j.critrevonc.2023.104134_bib64","doi-asserted-by":"crossref","first-page":"18","DOI":"10.21037\/sci-2021-008","article-title":"Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world setting","volume":"8","author":"Thakkar","year":"2021","journal-title":"Stem Cell Investig."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104134_bib65","article-title":"Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies","volume":"6","author":"Walti","year":"2021","journal-title":"JCI Insight"},{"issue":"14","key":"10.1016\/j.critrevonc.2023.104134_bib66","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"23","key":"10.1016\/j.critrevonc.2023.104134_bib67","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","article-title":"Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"5","author":"Wang","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2023.104134_bib68","unstructured":"Wong S.M., Shah M., Inam S., Kuhnl A., Sanderson R. Real-world data from Kings College Hospital: Infection complications post CAR-T treatment in high-grade B cell non-hodgkin lymphoma. Bone Marrow Transplantation. 2020;55((Wong, Shah, Inam, Kuhnl, Sanderson) Kings College Hospital NHS Foundation Trust, London, United Kingdom):237."},{"key":"10.1016\/j.critrevonc.2023.104134_bib69","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant."},{"issue":"3 Supplement","key":"10.1016\/j.critrevonc.2023.104134_bib70","doi-asserted-by":"crossref","first-page":"S326","DOI":"10.1016\/j.bbmt.2019.12.350","article-title":"Infectious complications in aggressive B cell non-hodgkin lymphoma after CD-19 chimeric antigen receptor T cell therapy","volume":"26","author":"Wudhikarn","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104134_bib71","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jcyt.2020.01.008","article-title":"Efficacy and toxicity for CD22\/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed\/refractory aggressive B-cell lymphoma involving the gastrointestinal tract","volume":"22","author":"Zeng","year":"2020","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104134_bib72","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41375-021-01345-8","article-title":"Long-term activity of tandem CD19\/CD20 CAR therapy in refractory\/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2023.104134_bib73","doi-asserted-by":"crossref","DOI":"10.1177\/09636897211025503","article-title":"Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T cell therapy for relapsed\/refractory B-cell malignancies","volume":"30","author":"Zhu","year":"2021","journal-title":"Cell Transpl."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104134_bib74","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3390\/curroncol29020044","article-title":"Cytomegalovirus retinitis and retinal detachment following chimeric antigen receptor T cell therapy for relapsed\/refractory multiple myeloma","volume":"29","author":"Zu","year":"2022","journal-title":"Curr Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823002226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823002226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:49:48Z","timestamp":1760903388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842823002226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":74,"alternative-id":["S1040842823002226"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104134","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infections in haematology patients treated with CAR-T therapies: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104134","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104134"}}